Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of GNC-035 in relapsed or refractory non-Hodgkin lymphoma and other hematologic malignancies
CTR20233127Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GNC-035 in non-Hodgkin lymphoma (NHL), hematopoietic malignancies, sponsored by Biokin Pharmaceutical. Started Nov 2023; status: active.
02
Drugs
GNC-035
03
Conditions
non-Hodgkin lymphoma (NHL)hematopoietic malignancies
Beyond the preview
Go deeper on CTR20233127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233127.